Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
Each line starts at 100 so growth is directly comparable
| Metric | JBIO | ANL |
|---|---|---|
| Price | $13.77 | $14.05 |
| Change today | ▲ 2.68% | ▼ 2.84% |
| Market cap | $875.74M | $904.79M |
| Return, 3 months | -38.7% | +31.6% |
| Return, year to date | -10.8% | +889.4% |
| Return, 1 year | +51.7% | +712.1% |
| P/E (TTM) | -12.9 | -21.3 |
| P/B | 2.0 | 4.2 |
| P/E percentile vs own 5y | 2nd | 2nd |
| Dividend yield | – | – |
| Revenue growth (YoY, latest qtr) | – | – |
| Net profit growth (YoY) | -73.5% | -1,715.5% |
| Gross margin | – | – |
| Operating margin | – | -123.5% |
| Net margin | – | -124.8% |
| Return on equity | -47.8% | -20.2% |
| Analyst target vs. price | +266.7% | +119.2% |
| Analyst buy share | 100% | 100% |
| RSI (14) | 26 | 42 |
| 30-day volatility | 53.8% | 62.2% |
| Max drawdown, 1 year | -50.1% | -51.1% |
| Trend read | Strong downtrend | Leaning bearish |
| Analyst consensus | Buy | Buy |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
